• The Accelerated Access Collaborative has determined that PCSK9 inhibitors are cost-effective drugs that significantly lower cholesterol, and have assigned them rapid uptake status1

    PCSK9 inhibitors are recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if LDL-C concentrations are persistently above the levels specified in the NICE TAG despite maximal tolerated lipid lowering therapy and agreed discounted price in PAS is met2

    The AAC is a unique partnership between patient groups, government bodies, industry and NHS bodies launched in 2018. These groups work together to speed up access to the most promising treatments and diagnostic tools that have the potential to benefit patients and save the NHS money3,4

    It is estimated that the 7 rapid uptake products selected and supported by the AAC will have the potential to improve the lives of 500,000 patients, with potential cost savings to the NHS of up to £30 million3

    UNMET NEED

    Learn more

    ODYSSEY OUTCOMES

    Learn more
    1. NICE. AAC Rapid Uptake Products. Available at: https://www.nice.org.uk/Media/Default/accelerated-access-collaborative/aac-rapid-uptake-products-list.pdf
    2. NICE Technology appraisal guidance [TA393]. Available at: https://www.nice.org.uk/guidance/ta393/chapter/1-Recommendations
    3. Department of Health and Social Care. NHS patients to get faster access to pioneering treatments. Available at: https://www.gov.uk/government/news/nhs-patients-to-get-faster-access-to-pioneering-treatments
    4. NHS Accelerated Access Collaborative - Who we are. Available at: https://www.england.nhs.uk/aac/about-us/who-we-are/